NuCana (NASDAQ:NCNA) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a buy rating in a report published on Saturday, Zacks.com reports. They currently have $11.00 target price on the stock.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

Several other brokerages have also weighed in on NCNA. William Blair reaffirmed an outperform rating on shares of NuCana in a research report on Thursday, May 16th. BidaskClub raised NuCana from a strong sell rating to a sell rating in a research report on Wednesday, July 31st. Finally, ValuEngine raised NuCana from a hold rating to a buy rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $23.50.

NASDAQ:NCNA opened at $9.10 on Friday. NuCana has a 1-year low of $7.53 and a 1-year high of $30.10. The company’s fifty day simple moving average is $9.51.

NuCana (NASDAQ:NCNA) last issued its earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, hitting the consensus estimate of ($0.22). Equities analysts predict that NuCana will post -1.14 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Asymmetry Capital Management L.P. boosted its stake in shares of NuCana by 257.8% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 162,414 shares of the company’s stock worth $1,686,000 after acquiring an additional 117,021 shares in the last quarter. Aperio Group LLC bought a new stake in shares of NuCana during the 2nd quarter worth about $39,000. Rothschild Investment Corp IL boosted its stake in shares of NuCana by 126.1% during the 2nd quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock worth $291,000 after acquiring an additional 15,660 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in shares of NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after acquiring an additional 51,607 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in shares of NuCana by 5.6% during the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock worth $1,323,000 after acquiring an additional 4,160 shares in the last quarter. 38.09% of the stock is currently owned by institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.